The influence of intravitreal ranibizumab on Iinflammation-associated cytokine concentrations in eyes with diabetic macular edema
- Author(s)
- Lim, SW; Bandala-Sanchez, E; Kolic, M; Rogers, SL; McAuley, AK; Lim, LL; Wickremasinghe, SS;
- Details
- Publication Year 2018-11-01,Volume 59,Issue #13,Page 5382-5390
- Journal Title
- Investigative Ophthalmology & Visual Science
- Publication Type
- Journal Article
- Abstract
- Purpose: To evaluate the effect of intravitreal ranibizumab injections on aqueous concentrations of angiogenic or inflammatory cytokines in patients with diabetic macular edema (DME). Methods: Thirty eyes of 25 patients with center-involved DME were recruited to the study. All had a central macular thickness (CMT) of >300 mum and best-corrected visual acuity (BCVA) between 28 and 70 logMAR letters (Snellen equivalent 20/320-20/40). At baseline, all eyes had 0.1 mL of aqueous collected before ranibizumab treatment. At week 4, a second ranibizumab injection was administered and at week 8, aqueous sampling was repeated before a third ranibizumab injection. From week 12, all eyes were followed at 4-weekly intervals and the need for ranibizumab treatment was determined by BCVA and CMT measurements. Levels of 32 cytokines were assessed at baseline and at week 8 using a multiplex array assay. Results: Following two consecutive ranibizumab injections, there was a statistically significant reduction in VEGF (P < 0.00001), as well as IL-1beta (P = 0.00006), IL-7 (P = 0.00002), IL-8 (P = 0.00023), IL-10 (P < 0.00001), IL-12 (P < 0.00001), IL-17 (P = 0.00024), MCP-1 (P = 0.00023), and TNF-alpha (P < 0.00001). There was also an upregulation of soluble VEGF receptor-2 (P = 0.00004). A P < 0.0015 was considered significant in this study. Conclusions: Ranibizumab treatment influences various inflammatory cytokine concentrations in addition to reducing aqueous VEGF concentrations in patients with DME. This may contribute to its therapeutic effect in patients with DME.
- Publisher
- ARVO
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 30452591
- Publisher's Version
- https://doi.org/10.1167/iovs.17-23325
- Open Access at Publisher's Site
https://doi.org/10.1167/iovs.17-23325- NHMRC Grants
- NHMRC/1128343, NHMRC/1109330,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2018-12-18 02:54:29
Last Modified: 2018-12-18 04:16:26